FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367669541> ?p ?o ?g. }

• W4367669541 abstract "Future OncologyAhead of Print EditorialNALIRIFOX in the upfront setting of metastatic pancreatic cancer: can FOLFIRINOX finally be dethroned?Rita Khoury, Rebecca Ibrahim, Tony Ibrahim, Axel Le Cesne & Tarek AssiRita KhouryDivision of International Patients Care, Gustave Roussy Cancer Campus, Villejuif, 94800, FranceSearch for more papers by this author, Rebecca IbrahimDivision of International Patients Care, Gustave Roussy Cancer Campus, Villejuif, 94800, FranceSearch for more papers by this author, Tony IbrahimDivision of International Patients Care, Gustave Roussy Cancer Campus, Villejuif, 94800, FranceSearch for more papers by this author, Axel Le CesneDivision of International Patients Care, Gustave Roussy Cancer Campus, Villejuif, 94800, FranceSearch for more papers by this author & Tarek Assi *Author for correspondence: Tel.: +33 767 129 224; E-mail Address: tarek.assi@gustaveroussy.fr; E-mail Address: tarekassi@gmail.comhttps://orcid.org/0000-0002-5579-5264Division of International Patients Care, Gustave Roussy Cancer Campus, Villejuif, 94800, FranceSearch for more papers by this authorPublished Online:2 May 2023https://doi.org/10.2217/fon-2023-0088AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: cancerchemotherapyNALIRIFOXpancreaticsurvivalPapers of special note have been highlighted as: • of interest; •• of considerable interestReferences1. Surveillance, Epidemiology, and End Results. Cancer of the pancreas – cancer stat facts, 2023. https://seer.cancer.gov/statfacts/html/pancreas.htmlGoogle Scholar2. Ghosn M, Ibrahim T, Assi T, El Rassy E, Kourie HR, Kattan J. Dilemma of first line regimens in metastatic pancreatic adenocarcinoma. World J. Gastroenterol. 22(46), 10124 (2016).Crossref, Medline, CAS, Google Scholar3. Burris HA, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 15(6), 2403–2413 (1997).Crossref, Medline, CAS, Google Scholar4. Conroy T, Desseigne F, Ychou M et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 364(19), 1817–1825 (2011). •• Pivotal phase III trial of FOLFIRINOX as a new standard-of-care in the first-line setting of metastatic pancreatic cancer.Crossref, Medline, CAS, Google Scholar5. Von Hoff DD, Ervin T, Arena FP et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 369(18), 1691–1703 (2013). • Pivotal trial of nab-paclitaxel and gemcitabine as a new standard-of-care in addition to FOLFIRINOX as an additional option in the first-line setting of metastatic pancreatic cancer.Crossref, Medline, CAS, Google Scholar6. Klein-Brill A, Amar-Farkash S, Lawrence G, Collisson EA, Aran D. Comparison of FOLFIRINOX vs gemcitabine plus nab-paclitaxel as first-line chemotherapy for metastatic pancreatic ductal adenocarcinoma. JAMA Netw. Open 5(6), e2216199 (2022).Crossref, Medline, Google Scholar7. Hegewisch-Becker S, Aldaoud A, Wolf T et al. Results from the prospective German TPK clinical cohort study: treatment algorithms and survival of 1,174 patients with locally advanced, inoperable, or metastatic pancreatic ductal adenocarcinoma. Int. J. Cancer 144(5), 981–990 (2019).Crossref, Medline, CAS, Google Scholar8. Muranaka T, Kuwatani M, Komatsu Y et al. Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer. J. Gastrointest. Oncol. 8(3), 566–571 (2017).Crossref, Medline, Google Scholar9. Hollmann S, Alloul K, Attard C, Kavan P. An indirect treatment comparison and cost-effectiveness analysis comparing folfirinox with nab-paclitaxel plus gemcitabine for first-line treatment for patients with metastatic pancreatic cancer. Ann. Oncol. 25(Suppl. 2), Abstract II11 (2014).Crossref, Google Scholar10. Akbarzadeh A, Rezaei-Sadabady R, Davaran S et al. Liposome: classification, preparation, and applications. Nanoscale Res. Lett. 8(1), 102 (2013).Crossref, Medline, Google Scholar11. Sachdev JC, Munster P, Northfelt DW et al. Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase. Breast Cancer Res. Treat. 185(3), 759–771 (2021).Crossref, Medline, CAS, Google Scholar12. Chiang N-J, Chao T-Y, Hsieh R-K et al. A phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors. BMC Cancer 16(1), 907 (2016).Crossref, Medline, Google Scholar13. Ko AH, Tempero MA, Shan Y-S et al. A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer. Br. J. Cancer 109(4), 920–925 (2013).Crossref, Medline, CAS, Google Scholar14. Wang-Gillam A, Li C-P, Bodoky G et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet 387(10018), 545–557 (2016).Crossref, Medline, CAS, Google Scholar15. Frampton JE. Liposomal irinotecan: a review in metastatic pancreatic adenocarcinoma. Drugs 80(10), 1007–1018 (2020).Crossref, Medline, CAS, Google Scholar16. Ducreux M, Cuhna AS, Caramella C et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 26(Suppl. 5), v56–68 (2015).Crossref, Medline, Google Scholar17. Sohal DPS, Kennedy EB, Khorana A et al. Metastatic pancreatic cancer: ASCO Clinical Practice Guideline Update. J. Clin. Oncol. 36(24), 2545–2556 (2018).Crossref, Medline, Google Scholar18. Wainberg ZA, Bekaii-Saab T, Boland PM et al. First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: a phase I/II study. Eur. J. Cancer 151, 14–24 (2021).Crossref, Medline, CAS, Google Scholar19. Wainberg ZA, Bekali-Saab TS, Hubner R et al. NAPOLI-3: an open-label, randomized, phase III study of first-line liposomal irinotecan+5-fluorouracil/leucovorin+oxaliplatin versus nab-paclitaxel+gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma. J. Clin. Oncol. 38(Suppl. 15), TPS4661 (2020). •• Crucial data demonstrating the superiority of NALIRIFOX compared with the standard-of-care (gemcitabine and nab-paclitaxel) in metastatic pancreatic cancer.Crossref, Google Scholar20. Chun JW, Lee SH, Kim JS et al. Comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel including sequential treatment for metastatic pancreatic cancer: a propensity score matching approach. BMC Cancer 21(1), 537 (2021).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetails Ahead of Print eToC Sign up Follow us on social media for the latest updates Metrics Downloaded 0 times History Received 1 February 2023 Accepted 6 March 2023 Published online 2 May 2023 Information© 2023 Future Medicine LtdKeywordscancerchemotherapyNALIRIFOXpancreaticsurvivalAuthor contributionsR Khoury: writing (original draft), conceptualization. R Ibrahim: writing (original draft). T Ibrahim: writing (review and editing), validation, supervision. A Le Cesne: writing (review and editing), validation, supervision. T Assi: writing (original draft), conceptualization.Financial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download" @default.
• W4367669541 created "2023-05-03" @default.
• W4367669541 creator A5001102421 @default.
• W4367669541 creator A5033157419 @default.
• W4367669541 creator A5048027221 @default.
• W4367669541 creator A5066080117 @default.
• W4367669541 creator A5068927402 @default.
• W4367669541 date "2023-05-02" @default.
• W4367669541 modified "2023-09-29" @default.
• W4367669541 title "NALIRIFOX in the upfront setting of metastatic pancreatic cancer: can FOLFIRINOX finally be dethroned?" @default.
• W4367669541 cites W1931508686 @default.
• W4367669541 cites W2072714492 @default.
• W4367669541 cites W2097603366 @default.
• W4367669541 cites W2107780185 @default.
• W4367669541 cites W2115275439 @default.
• W4367669541 cites W2151253787 @default.
• W4367669541 cites W2165480504 @default.
• W4367669541 cites W2187917981 @default.
• W4367669541 cites W2549335337 @default.
• W4367669541 cites W2561779550 @default.
• W4367669541 cites W2599017064 @default.
• W4367669541 cites W2804017601 @default.
• W4367669541 cites W2884529066 @default.
• W4367669541 cites W3031287584 @default.
• W4367669541 cites W3035998918 @default.
• W4367669541 cites W3101578464 @default.
• W4367669541 cites W3157420478 @default.
• W4367669541 cites W3161080579 @default.
• W4367669541 cites W4282919273 @default.
• W4367669541 doi "https://doi.org/10.2217/fon-2023-0088" @default.
• W4367669541 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37129008" @default.
• W4367669541 hasPublicationYear "2023" @default.
• W4367669541 type Work @default.
• W4367669541 citedByCount "0" @default.
• W4367669541 crossrefType "journal-article" @default.
• W4367669541 hasAuthorship W4367669541A5001102421 @default.
• W4367669541 hasAuthorship W4367669541A5033157419 @default.
• W4367669541 hasAuthorship W4367669541A5048027221 @default.
• W4367669541 hasAuthorship W4367669541A5066080117 @default.
• W4367669541 hasAuthorship W4367669541A5068927402 @default.
• W4367669541 hasConcept C121608353 @default.
• W4367669541 hasConcept C126322002 @default.
• W4367669541 hasConcept C143998085 @default.
• W4367669541 hasConcept C2777148230 @default.
• W4367669541 hasConcept C2780210213 @default.
• W4367669541 hasConcept C2780962732 @default.
• W4367669541 hasConcept C526805850 @default.
• W4367669541 hasConcept C71924100 @default.
• W4367669541 hasConceptScore W4367669541C121608353 @default.
• W4367669541 hasConceptScore W4367669541C126322002 @default.
• W4367669541 hasConceptScore W4367669541C143998085 @default.
• W4367669541 hasConceptScore W4367669541C2777148230 @default.
• W4367669541 hasConceptScore W4367669541C2780210213 @default.
• W4367669541 hasConceptScore W4367669541C2780962732 @default.
• W4367669541 hasConceptScore W4367669541C526805850 @default.
• W4367669541 hasConceptScore W4367669541C71924100 @default.
• W4367669541 hasLocation W43676695411 @default.
• W4367669541 hasLocation W43676695412 @default.
• W4367669541 hasOpenAccess W4367669541 @default.
• W4367669541 hasPrimaryLocation W43676695411 @default.
• W4367669541 hasRelatedWork W2012954058 @default.
• W4367669541 hasRelatedWork W2138640290 @default.
• W4367669541 hasRelatedWork W2599910524 @default.
• W4367669541 hasRelatedWork W2910998150 @default.
• W4367669541 hasRelatedWork W2941837211 @default.
• W4367669541 hasRelatedWork W2966671351 @default.
• W4367669541 hasRelatedWork W3008650849 @default.
• W4367669541 hasRelatedWork W3046481916 @default.
• W4367669541 hasRelatedWork W3154040450 @default.
• W4367669541 hasRelatedWork W4229863258 @default.
• W4367669541 isParatext "false" @default.
• W4367669541 isRetracted "false" @default.
• W4367669541 workType "article" @default.